In 2015 Novartis expects sales to increase even despite a drop in the sales of some products. Its oncology division predicts growth of 4.7%. The pharmaceutical company stated this in its annual report. In 2014 revenues from the sale of products totaled CZK 3.03 billion and revenues from the sale of own products and services totaled CZK 1.65bn. Its profits before taxes totaled CZK 89.24m. Novartis wants to continue to provide global IT services.